
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Merck and Idera to develop TLR9 agonists for treatment of cancer
Merck and Idera to develop TLR9 agonists for treatment of cancer
DARMSTADT, Germany-Merck KGaA has entered into a worldwide licensing and collaboration agreement, on behalf of its Merck Serono division, with Idera Pharmaceuticals of Cambridge, Massachusetts, for the research, development, and commercialization of Idera's toll-like receptor 9 (TLR9) agonists IMO-2055 and IMO-2125, and any follow-on TLR9 agonists identified through the collaboration.
Articles in this issue
about 18 years ago
New tobacco product alert: Camel Snus is on the looseabout 18 years ago
Blueberry punch not quite a 'knock out' blowabout 18 years ago
Texas voters listen to Lanceabout 18 years ago
Cellectar opens manufacturing facility for radiolabeled CLR1404about 18 years ago
High cost of breast MRI screening appears to be justifiedabout 18 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskabout 18 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caabout 18 years ago
Statins during RT may lower risk of prostate ca relapseNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































